Abstract
Genotoxic anticancer drugs explicate their effects damaging DNA, thus triggering a coordinated signal-transduction network called DNA Damage Response (DDR). Ataxia Telangiectasia Mutated (ATM) protein plays a central role in this response: activated by DNA damage, ATM phosphorylates itself and downstream effectors that arrest cell cycle allowing for DNA repair or, should DNA damage be too severe and not retrievable, inducing apoptosis. ATM is a worth-investigating target for tumor radio- and chemosensitization. During last years, pharmaceutical industries and research laboratories have developed a series of small molecules, capable to inhibit ATM with increasing specificity. Several preclinical studies have demonstrated that these inhibitors alone or in association with other treatments may improve therapeutic outcomes. In this review we discuss ATM inhibitors so far developed, focussing on recent acquisitions on their potential antineoplastic usefulness.
Keywords: ATM, chemotherapy, glioma, inhibitor, radiotherapy, resistance, sensitization.
Current Drug Targets
Title:Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Volume: 17 Issue: 2
Author(s): Donatella Vecchio and Guido Frosina
Affiliation:
Keywords: ATM, chemotherapy, glioma, inhibitor, radiotherapy, resistance, sensitization.
Abstract: Genotoxic anticancer drugs explicate their effects damaging DNA, thus triggering a coordinated signal-transduction network called DNA Damage Response (DDR). Ataxia Telangiectasia Mutated (ATM) protein plays a central role in this response: activated by DNA damage, ATM phosphorylates itself and downstream effectors that arrest cell cycle allowing for DNA repair or, should DNA damage be too severe and not retrievable, inducing apoptosis. ATM is a worth-investigating target for tumor radio- and chemosensitization. During last years, pharmaceutical industries and research laboratories have developed a series of small molecules, capable to inhibit ATM with increasing specificity. Several preclinical studies have demonstrated that these inhibitors alone or in association with other treatments may improve therapeutic outcomes. In this review we discuss ATM inhibitors so far developed, focussing on recent acquisitions on their potential antineoplastic usefulness.
Export Options
About this article
Cite this article as:
Vecchio Donatella and Frosina Guido, Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy, Current Drug Targets 2016; 17 (2) . https://dx.doi.org/10.2174/1389450115666141110154621
DOI https://dx.doi.org/10.2174/1389450115666141110154621 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunogenic Issues Concerning Recombinant Adeno-Associated Virus Vectors for Gene Therapy
Current Gene Therapy Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism Antiviral Compounds Derived from Naturally Occurring Proteins
Current Medicinal Chemistry - Anti-Infective Agents Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Mucosal Vaccine Vectors: Replication-Competent Versus Replication-Deficient Poxviruses
Current Pharmaceutical Design Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Analysis of Codon Usage Patterns in the Human Papillomavirus Oncogenes
Current Bioinformatics The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry Prostate Cancer Prevention in the Developing World - What are we Waiting for?
Current Pharmacogenomics and Personalized Medicine SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Liquid-based Cytology With HPV Triage of Low-grade Cytological Abnormalities Versus Conventional Cytology in Cervical Cancer Screening
Current Pharmaceutical Design HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines
Current Molecular Medicine From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Photopolymerizable Resins for 3D-Printing Solid-Cured Tissue Engineered Implants
Current Drug Targets Prevalence of Breast Complaints in Women with Mastopathy in Khorramabad
Current Women`s Health Reviews miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Lessons from Viruses: Controlling the Function of Transmembrane Proteins by Interfering Transmembrane Helices
Current Medicinal Chemistry Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry